Madrigal Pharmaceuticals/MDGL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Ticker

MDGL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Bill Sibold

Employees

376

Headquarters

West conshohocken, United States

MDGL Metrics

BasicAdvanced
$5B
Market cap
-
P/E ratio
-$23.08
EPS
-0.41
Beta
-
Dividend rate
$5B
-0.41266
$299.98
$119.76
511K
9.393
9.385
13.651
13.651
-62.81%
-88.78%
-73.92%
5.742
5.951
-27.56%

What the Analysts think about MDGL

Analyst Ratings

Majority rating from 15 analysts.
Buy

MDGL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$148M
31.58%
Profit margin
0.00%
NaN%

MDGL Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 17.42%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$4.69
-$5.34
-$5.68
-$7.38
-
Expected
-$4.58
-$4.93
-$5.28
-$6.29
-$7.56
Surprise
2.37%
8.42%
7.49%
17.42%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Madrigal Pharmaceuticals stock?

Madrigal Pharmaceuticals (MDGL) has a market cap of $5B as of June 20, 2024.

What is the P/E ratio for Madrigal Pharmaceuticals stock?

The price to earnings (P/E) ratio for Madrigal Pharmaceuticals (MDGL) stock is 0 as of June 20, 2024.

Does Madrigal Pharmaceuticals stock pay dividends?

No, Madrigal Pharmaceuticals (MDGL) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Madrigal Pharmaceuticals dividend payment date?

Madrigal Pharmaceuticals (MDGL) stock does not pay dividends to its shareholders.

What is the beta indicator for Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (MDGL) has a beta rating of -0.41. This means that it has an inverse relation to market volatility.

What is the Madrigal Pharmaceuticals stock price target?

The target price for Madrigal Pharmaceuticals (MDGL) stock is $363.86, which is NaN% below the current price of $. This is an average based on projections from 14 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Madrigal Pharmaceuticals stock

Buy or sell Madrigal Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing